A detailed history of Walleye Capital LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Walleye Capital LLC holds 4,095 shares of BMY stock, worth $238,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,095
Previous 435,800 99.06%
Holding current value
$238,451
Previous $18.1 Million 98.83%
% of portfolio
0.0%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $7.07 Million - $9.22 Million
-178,207 Reduced 97.75%
4,095 $211,000
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $7.34 Million - $9.66 Million
182,302 New
182,302 $7.57 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $13 Million - $14.5 Million
223,808 New
223,808 $13 Million
Q2 2022

Aug 08, 2022

SELL
$72.62 - $79.98 $1.31 Million - $1.44 Million
-18,007 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $2.27 Million - $2.72 Million
-36,897 Reduced 67.2%
18,007 $1.32 Million
Q4 2021

Mar 03, 2022

BUY
$53.63 - $62.52 $2.94 Million - $3.43 Million
54,904 New
54,904 $3.42 Million
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $912,811 - $1.03 Million
-15,809 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $473,280 - $524,457
8,241 Added 108.89%
15,809 $953,000
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $414,877 - $485,033
7,568 New
7,568 $445,000
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $193,488 - $281,183
-4,170 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $146,153 - $190,644
2,970 Added 247.5%
4,170 $268,000
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $25,662 - $30,426
600 Added 100.0%
1,200 $61,000
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $27,072 - $32,280
600 New
600 $29,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.